Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

Yasushi Yatabe, Sanja Dacic, Alain C. Borczuk, Arne Warth, Prudence A. Russell, Sylvie Lantuejoul, Mary Beth Beasley, Erik Thunnissen, Giuseppe Pelosi, Natasha Rekhtman, Lukas Bubendorf, Mari Mino-Kenudson, Akihiko Yoshida, Kim R. Geisinger, Masayuki Noguchi, Lucian R. Chirieac, Johan Bolting, Jin-Haeng Chung, Teh-Ying Chou, Gang Chen & 12 others Claudia Poleri, Fernando Lopez-Rios, Mauro Papotti, Lynette M. Sholl, Anja C. Roden, William D. Travis, Fred R. Hirsch, Keith M. Kerr, Ming-Sound Tsao, Andrew G. Nicholson, Ignacio Wistuba, Andre L. Moreira

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Since the 2015 WHO classification was introduced into clinical practice, immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small cell versus non–small cell carcinoma, patients’ treatment of choice is directly linked to histologic subtypes of non–small cell carcinoma, which pertains to IHC results, particularly for poorly differentiated tumors. The use of IHC has improved diagnostic accuracy in the classification of lung carcinoma, but the interpretation of IHC results remains challenging in some instances. Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular testing. The International Association for the Study of Lung Cancer Pathology Committee received questions on practical application and interpretation of IHC in lung cancer diagnosis. After discussions in several International Association for the Study of Lung Cancer Pathology Committee meetings, the issues and caveats were summarized in terms of 11 key questions covering common and important diagnostic situations in a daily clinical practice with some relevant challenging queries. The questions cover topics such as the best IHC markers for distinguishing NSCLC subtypes, differences in thyroid transcription factor 1 clones, and the utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors. This article provides answers and explanations for the key questions about the use of IHC in diagnosis of lung carcinoma, representing viewpoints of experts in thoracic pathology that should assist the community in the appropriate use of IHC in diagnostic pathology.
Original languageEnglish
Pages (from-to)377-407
JournalJournal of Thoracic Oncology
Volume14
Issue number3
DOIs
Publication statusPublished - 2019

Cite this

Yatabe, Y., Dacic, S., Borczuk, A. C., Warth, A., Russell, P. A., Lantuejoul, S., ... Moreira, A. L. (2019). Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology, 14(3), 377-407. https://doi.org/10.1016/j.jtho.2018.12.005
Yatabe, Yasushi ; Dacic, Sanja ; Borczuk, Alain C. ; Warth, Arne ; Russell, Prudence A. ; Lantuejoul, Sylvie ; Beasley, Mary Beth ; Thunnissen, Erik ; Pelosi, Giuseppe ; Rekhtman, Natasha ; Bubendorf, Lukas ; Mino-Kenudson, Mari ; Yoshida, Akihiko ; Geisinger, Kim R. ; Noguchi, Masayuki ; Chirieac, Lucian R. ; Bolting, Johan ; Chung, Jin-Haeng ; Chou, Teh-Ying ; Chen, Gang ; Poleri, Claudia ; Lopez-Rios, Fernando ; Papotti, Mauro ; Sholl, Lynette M. ; Roden, Anja C. ; Travis, William D. ; Hirsch, Fred R. ; Kerr, Keith M. ; Tsao, Ming-Sound ; Nicholson, Andrew G. ; Wistuba, Ignacio ; Moreira, Andre L. / Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. In: Journal of Thoracic Oncology. 2019 ; Vol. 14, No. 3. pp. 377-407.
@article{a26f95ed3e1745a28c3fc299e40ef882,
title = "Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer",
abstract = "Since the 2015 WHO classification was introduced into clinical practice, immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small cell versus non–small cell carcinoma, patients’ treatment of choice is directly linked to histologic subtypes of non–small cell carcinoma, which pertains to IHC results, particularly for poorly differentiated tumors. The use of IHC has improved diagnostic accuracy in the classification of lung carcinoma, but the interpretation of IHC results remains challenging in some instances. Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular testing. The International Association for the Study of Lung Cancer Pathology Committee received questions on practical application and interpretation of IHC in lung cancer diagnosis. After discussions in several International Association for the Study of Lung Cancer Pathology Committee meetings, the issues and caveats were summarized in terms of 11 key questions covering common and important diagnostic situations in a daily clinical practice with some relevant challenging queries. The questions cover topics such as the best IHC markers for distinguishing NSCLC subtypes, differences in thyroid transcription factor 1 clones, and the utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors. This article provides answers and explanations for the key questions about the use of IHC in diagnosis of lung carcinoma, representing viewpoints of experts in thoracic pathology that should assist the community in the appropriate use of IHC in diagnostic pathology.",
author = "Yasushi Yatabe and Sanja Dacic and Borczuk, {Alain C.} and Arne Warth and Russell, {Prudence A.} and Sylvie Lantuejoul and Beasley, {Mary Beth} and Erik Thunnissen and Giuseppe Pelosi and Natasha Rekhtman and Lukas Bubendorf and Mari Mino-Kenudson and Akihiko Yoshida and Geisinger, {Kim R.} and Masayuki Noguchi and Chirieac, {Lucian R.} and Johan Bolting and Jin-Haeng Chung and Teh-Ying Chou and Gang Chen and Claudia Poleri and Fernando Lopez-Rios and Mauro Papotti and Sholl, {Lynette M.} and Roden, {Anja C.} and Travis, {William D.} and Hirsch, {Fred R.} and Kerr, {Keith M.} and Ming-Sound Tsao and Nicholson, {Andrew G.} and Ignacio Wistuba and Moreira, {Andre L.}",
year = "2019",
doi = "10.1016/j.jtho.2018.12.005",
language = "English",
volume = "14",
pages = "377--407",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "3",

}

Yatabe, Y, Dacic, S, Borczuk, AC, Warth, A, Russell, PA, Lantuejoul, S, Beasley, MB, Thunnissen, E, Pelosi, G, Rekhtman, N, Bubendorf, L, Mino-Kenudson, M, Yoshida, A, Geisinger, KR, Noguchi, M, Chirieac, LR, Bolting, J, Chung, J-H, Chou, T-Y, Chen, G, Poleri, C, Lopez-Rios, F, Papotti, M, Sholl, LM, Roden, AC, Travis, WD, Hirsch, FR, Kerr, KM, Tsao, M-S, Nicholson, AG, Wistuba, I & Moreira, AL 2019, 'Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer' Journal of Thoracic Oncology, vol. 14, no. 3, pp. 377-407. https://doi.org/10.1016/j.jtho.2018.12.005

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. / Yatabe, Yasushi; Dacic, Sanja; Borczuk, Alain C.; Warth, Arne; Russell, Prudence A.; Lantuejoul, Sylvie; Beasley, Mary Beth; Thunnissen, Erik; Pelosi, Giuseppe; Rekhtman, Natasha; Bubendorf, Lukas; Mino-Kenudson, Mari; Yoshida, Akihiko; Geisinger, Kim R.; Noguchi, Masayuki; Chirieac, Lucian R.; Bolting, Johan; Chung, Jin-Haeng; Chou, Teh-Ying; Chen, Gang; Poleri, Claudia; Lopez-Rios, Fernando; Papotti, Mauro; Sholl, Lynette M.; Roden, Anja C.; Travis, William D.; Hirsch, Fred R.; Kerr, Keith M.; Tsao, Ming-Sound; Nicholson, Andrew G.; Wistuba, Ignacio; Moreira, Andre L.

In: Journal of Thoracic Oncology, Vol. 14, No. 3, 2019, p. 377-407.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

AU - Yatabe, Yasushi

AU - Dacic, Sanja

AU - Borczuk, Alain C.

AU - Warth, Arne

AU - Russell, Prudence A.

AU - Lantuejoul, Sylvie

AU - Beasley, Mary Beth

AU - Thunnissen, Erik

AU - Pelosi, Giuseppe

AU - Rekhtman, Natasha

AU - Bubendorf, Lukas

AU - Mino-Kenudson, Mari

AU - Yoshida, Akihiko

AU - Geisinger, Kim R.

AU - Noguchi, Masayuki

AU - Chirieac, Lucian R.

AU - Bolting, Johan

AU - Chung, Jin-Haeng

AU - Chou, Teh-Ying

AU - Chen, Gang

AU - Poleri, Claudia

AU - Lopez-Rios, Fernando

AU - Papotti, Mauro

AU - Sholl, Lynette M.

AU - Roden, Anja C.

AU - Travis, William D.

AU - Hirsch, Fred R.

AU - Kerr, Keith M.

AU - Tsao, Ming-Sound

AU - Nicholson, Andrew G.

AU - Wistuba, Ignacio

AU - Moreira, Andre L.

PY - 2019

Y1 - 2019

N2 - Since the 2015 WHO classification was introduced into clinical practice, immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small cell versus non–small cell carcinoma, patients’ treatment of choice is directly linked to histologic subtypes of non–small cell carcinoma, which pertains to IHC results, particularly for poorly differentiated tumors. The use of IHC has improved diagnostic accuracy in the classification of lung carcinoma, but the interpretation of IHC results remains challenging in some instances. Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular testing. The International Association for the Study of Lung Cancer Pathology Committee received questions on practical application and interpretation of IHC in lung cancer diagnosis. After discussions in several International Association for the Study of Lung Cancer Pathology Committee meetings, the issues and caveats were summarized in terms of 11 key questions covering common and important diagnostic situations in a daily clinical practice with some relevant challenging queries. The questions cover topics such as the best IHC markers for distinguishing NSCLC subtypes, differences in thyroid transcription factor 1 clones, and the utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors. This article provides answers and explanations for the key questions about the use of IHC in diagnosis of lung carcinoma, representing viewpoints of experts in thoracic pathology that should assist the community in the appropriate use of IHC in diagnostic pathology.

AB - Since the 2015 WHO classification was introduced into clinical practice, immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small cell versus non–small cell carcinoma, patients’ treatment of choice is directly linked to histologic subtypes of non–small cell carcinoma, which pertains to IHC results, particularly for poorly differentiated tumors. The use of IHC has improved diagnostic accuracy in the classification of lung carcinoma, but the interpretation of IHC results remains challenging in some instances. Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular testing. The International Association for the Study of Lung Cancer Pathology Committee received questions on practical application and interpretation of IHC in lung cancer diagnosis. After discussions in several International Association for the Study of Lung Cancer Pathology Committee meetings, the issues and caveats were summarized in terms of 11 key questions covering common and important diagnostic situations in a daily clinical practice with some relevant challenging queries. The questions cover topics such as the best IHC markers for distinguishing NSCLC subtypes, differences in thyroid transcription factor 1 clones, and the utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors. This article provides answers and explanations for the key questions about the use of IHC in diagnosis of lung carcinoma, representing viewpoints of experts in thoracic pathology that should assist the community in the appropriate use of IHC in diagnostic pathology.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85061730030&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30572031

U2 - 10.1016/j.jtho.2018.12.005

DO - 10.1016/j.jtho.2018.12.005

M3 - Article

VL - 14

SP - 377

EP - 407

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -